BioTissue Holdings Inc. FDA Inspection Record

FEI 3009809074 · Inspections, Form 483s, warning letters and import refusals

BioTissue Holdings Inc. is an FDA-registered facility (FEI 3009809074) located in Doral, FL, US. RegDataLab tracks 11 FDA inspections at this facility.

What FDA found at this site

Latest inspection
Sep 1, 2026: Official Action Indicated (OAI)
Inspections on record
11 (1 OAI, 4 VAI, 6 NAI)
Last OAI inspection
Sep 1, 2026
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
2, latest Oct 20, 2023

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Showing the 10 most recent of 11 inspections. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Sep 1, 2026Official Action Indicated (OAI)No citations listed
Feb 18, 2026Voluntary Action Indicated (VAI)Information gathered in feedback process not used as input into risk management (ISO 13485:2016 Clause 8.2.1)
Corrective action not taken (ISO 13485:2016 Clause 8.5.2)
Report of Death or Serious Injury (21 CFR 803.50(a)(1))
Mar 6, 2024Voluntary Action Indicated (VAI)Investigation of device failures (21 CFR 820.198(c))
Documentation (21 CFR 820.100(b))
Report of Death or Serious Injury (21 CFR 803.50(a)(1))
Individual Report of Malfunction (21 CFR 803.50(a)(2))
Aug 15, 2019No Action Indicated (NAI)No citations listed
Jul 16, 2019Voluntary Action Indicated (VAI)Procedures not adequately established or maintained (21 CFR 820.40)
Lack of or inadequate procedures (21 CFR 820.100(a))
Product rework procedures, Lack of or inadequate procedures (21 CFR 820.90(b)(2))
Process control procedures, Lack of or inadequate procedures (21 CFR 820.70(a))
and 1 more
Feb 6, 2018Voluntary Action Indicated (VAI)Testing, screening, donor eligibility procedures (21 CFR 1271.47(a))
Risk factors, clinical evidence (21 CFR 1271.75(a)(1))
Documentation of activities (21 CFR 1271.190(d)(2))
Corrective actions (21 CFR 1271.195(b))
and 7 more
Oct 29, 2015No Action Indicated (NAI)No citations listed
Jul 7, 2015No Action Indicated (NAI)No citations listed
Sep 25, 2014No Action Indicated (NAI)No citations listed
Dec 9, 2013No Action Indicated (NAI)Design changes - Lack of or Inadequate Procedures (21 CFR 820.30(i))

Recalls

Newest first. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Oct 20, 2023Class IIB-0372-2024Amniotic Membrane
Human tissue allografts, which did not meet release criteria designed to prevent communicable disease transmission, were distributed.
Nov 10, 2020Class IIZ-0550-2021PROKERA, non-sterile - Product Usage: Biologic corneal bandage. and 2 more products
Potential exposure of product to microbial contamination.

FDA record score

45 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 17, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

7 records behind this number
RecordDatePoints x age weightAdds
Inspection classified OAISep 1, 202630 x 130
Inspection classified VAIFeb 18, 20266 x 16
Inspection classified VAIMar 6, 20246 x 0.63.6
Class II recall B-0372-2024, this FEI as the recalling firmOct 20, 20234 x 0.62.4
Inspection classified VAIJul 16, 20196 x 0.251.5
Class II recall Z-0550-2021, this FEI as the recalling firmNov 10, 20204 x 0.251
Inspection classified VAIFeb 6, 2018Only the 3 most recent VAI inspections add points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 17, 2026Newest record Nov 9, 2026Current
Inspection citationsNov 17, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 17, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 17, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 17, 2026Newest record Nov 16, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing BioTissue Holdings Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check BioTissue Holdings Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
BioTissue Holdings Inc
Location
Doral, FL (US)
Source
device

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.